PLEASE NOTE: Legislative Information cannot perform research, provide legal advice, or interpret Maine law. For legal assistance, please contact a qualified attorney.
An Act To Improve Accountability of Opioid Manufacturers
Be it enacted by the People of the State of Maine as follows:
Sec. 1.  5 MRSA §20010  is enacted to read:
§ 20010. Opioid Use Disorder Prevention and Treatment Fund
 
1.  Fund established.     The Opioid Use Disorder Prevention and Treatment Fund, referred to in this section as "the fund," is established for the purpose of supporting opioid use disorder analysis, prevention and treatment and is administered by the department. The fund consists of:
 
A.  Money received from proceeds from the registration fee under Title 32, section 13800-C;
 
B.  Money received from proceeds from the fee under Title 32, section 13724, less $325, which may be retained by the Department of Professional and Financial Regulation; and
 
C.  Appropriations, allocations and contributions from private and public sources.
 
The fund must be held separate and apart from all other money, funds and accounts. Eligible investment earnings credited to the assets of the fund become part of the assets of the fund. Any unexpended balances remaining in the fund at the end of any fiscal year do not lapse and must be carried forward to the next fiscal year.
 
2.  Uses of fund proceeds.     The proceeds of the fund must be used for the following purposes:
 
A.  Opioid use disorder prevention services;
 
B.  Opioid use disorder treatment services, including:
 
(1) Inpatient and outpatient treatment programs and facilities, including short-term and long-term residential treatment programs and sober living facilities;
 
(2) Treating substance use disorder for the underinsured and uninsured; and
 
(3) Research regarding opioid use disorder prevention and treatment;
 
C.  The department's reasonable expenses in administering the fund; and
 
D.  The Maine Board of Pharmacy's reasonable expenses in administering Title 32, section 13800-C and in providing the report required under Title 32, section 13800-C.
 
The department shall award grants and contracts from proceeds of the fund to persons and organizations to carry out the purposes of the fund.
Sec. 2.  22 MRSA §7249-B  is enacted to read:
§ 7249-B. Opioid medication distribution monitoring information
A manufacturer of an opioid medication that is available in this State and a wholesaler that sells or distributes an opioid medication in this State shall submit to the department, by electronic means or other format specified in a waiver granted by the department, information for this State submitted to the United States Drug Enforcement Administration's Automation of Reports and Consolidated Orders System pursuant to 21 United States Code, Subchapter I and 21 Code of Federal Regulations, Section 1304.33 at the time that information is submitted to the United States Drug Enforcement Administration. As used in this section, the terms "manufacturer" and "opioid medication" have the same meanings as in Title 32, section 13702-A.
Sec. 3. 32 MRSA §13724, as amended by PL 2007, c. 402, Pt. DD, §11 and PL 2011, c. 286, Pt. B, §5, is repealed and the following enacted in its place:
§ 13724. Fees
The Director of the Office of Professional and Occupational Regulation may establish by rule fees for purposes authorized under this chapter in amounts that are reasonable and necessary for their respective purposes in accordance with this section. Rules adopted pursuant to this section are routine technical rules as defined in Title 5, chapter 375, subchapter 2-A.
 
1.  General fees.     Except as provided in subsection 2, the fee for any one purpose may not exceed $325.
 
2.  Manufacturer of an opioid medication fee.     The fee for a manufacturer of an opioid medication is $55,000. This subsection does not apply to a manufacturer of an opioid medication if all of that manufacturer's opioid medications are approved by the United States Food and Drug Administration for use only in veterinary medicine.
Sec. 4.  32 MRSA §13800-C  is enacted to read:
§ 13800-C. Opioid medication product registration fee
This section governs opioid medication product registration fees. As used in this section, "unit of an opioid medication" means the lowest identifiable quantity of the opioid medication that is dispensed.
 
1.  Registration fee.     Except as provided in subsection 2, a manufacturer that sells, delivers or distributes an opioid medication in this State shall pay an annual registration fee of $250,000 to the board on December 31st of each year.
 
2.  Exception.     A manufacturer that does not sell, deliver or distribute 2,000,000 or more units of an opioid medication within this State in the year in which a registration fee is due is not required to pay the registration fee. To qualify for the exception under this subsection, a manufacturer must demonstrate to the board, by January 31st of the year following the year in which the registration fee is due, in a manner determined by the board, that the manufacturer did not sell, deliver or distribute 2,000,000 or more units of an opioid medication within this State in the year in which the manufacturer seeks to claim the exception. The board may adopt rules to implement this section. Rules adopted pursuant to this subsection are routine technical rules as defined in Title 5, chapter 375, subchapter 2-A.
 
3.  Calculation of units of an opioid medication sold, delivered or distributed.     When calculating the number of units of an opioid medication sold, delivered or distributed by a manufacturer under subsection 2, units of an opioid medication may be excluded when prescribed for the purpose of medication-assisted treatment of substance use disorder. The board periodically shall provide to the Department of Health and Human Services a list of medications exempted under this subsection.
 
4.  Registration fee review and report.     By March 1st of each year following calendar years 2020, 2021 and 2022, the board shall evaluate and report whether the registration fee due under this section and the fee due under section 13724 have affected the prescribing practices of opioid medications by reducing the number of opioid medication prescriptions issued during calendar years 2020, 2021 and 2022 or whether the fees have created any unintended consequences in the availability of opioid medications for the treatment of chronic or intractable pain, to the extent the board has the ability to identify a correlation. The board shall provide the report to the joint standing committee of the Legislature having jurisdiction over health and human services matters, which may report out legislation based upon the report.
 
This subsection is repealed September 1, 2023.
Sec. 5. Appropriations and allocations. The following appropriations and allocations are made.
 
HEALTH AND HUMAN SERVICES, DEPARTMENT OF
 
Opioid Use Disorder Prevention and Treatment Fund N307
 
Initiative: Provides base allocation for the Opioid Use Disorder Prevention and Treatment Fund.

OTHER SPECIAL REVENUE FUNDS	2019-20	2020-21	
All Other	$500	$500	
			
OTHER SPECIAL REVENUE FUNDS TOTAL	$500	$500	

HEALTH AND HUMAN SERVICES, DEPARTMENT OF			
DEPARTMENT TOTALS	2019-20	2020-21	
			
OTHER SPECIAL REVENUE FUNDS	$500	$500	
			
DEPARTMENT TOTAL - ALL FUNDS	$500	$500	

PROFESSIONAL AND FINANCIAL REGULATION, DEPARTMENT OF
 
Licensing and Enforcement 0352
 
Initiative: Allocates funds for the contracting and general operating costs associated with the development of the registration fee review report, determination and report of exempted medications, rulemaking and additional board meetings.

OTHER SPECIAL REVENUE FUNDS	2019-20	2020-21	
All Other	$53,000	$53,000	
			
OTHER SPECIAL REVENUE FUNDS TOTAL	$53,000	$53,000	

PROFESSIONAL AND FINANCIAL REGULATION, DEPARTMENT OF			
DEPARTMENT TOTALS	2019-20	2020-21	
			
OTHER SPECIAL REVENUE FUNDS	$53,000	$53,000	
			
DEPARTMENT TOTAL - ALL FUNDS	$53,000	$53,000	

SECTION TOTALS	2019-20	2020-21	
			
OTHER SPECIAL REVENUE FUNDS	$53,500	$53,500	
			
SECTION TOTAL - ALL FUNDS	$53,500	$53,500	

Effective 90 days following adjournment of the 129th Legislature, Second Regular Session, unless otherwise indicated.